SynbioX

With the rapid rise of chronic diseases and ongoing medicine shortages, the pharmaceutical industry is investing heavily in the development of biologics—highly effective therapeutic agents with specificity capabilities beyond traditional small-molecule drugs. However, unlike small molecules, producing biologics, such as proteins or antibodies, involves complex challenges that impact the entire drug pipeline.

Pharma and biotech companies in the biologic field face lengthy R&D timelines, high failure rates, production inefficiencies, and significant waste generation. These factors drive up production costs, increase batch rejections, intensify purification requirements, and introduce manufacturing inconsistencies, limiting the industry’s ability to deliver transformative biological treatments to patients.

As part of TNO’s Tech Transfer program, SynBioX offers a sustainable and scalable solution for the efficient production of biologics. SynBioX ensures batch consistency, streamlines purification, shortens development timelines, reduces costs, and enables the synthesis of new drug modalities that surpass current biomanufacturing capabilities. Building on the success of Batavia Biosciences, SynBioX is TNO’s second venture that aims redefining the manufacturing of biologics—empowering companies to bring next-generation medicines to market faster and more efficiently.